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Summary
Evaluation of antimalarial efficacy is difficult because recurrent parasitemia can be due to 
recrudescence or reinfection. PCR is used to differentiate between recrudescences and reinfections 
by comparing parasite allelic variants before and after treatment. However, PCR-corrected results 
are susceptible to misclassification: false recrudescences, due to reinfection by the same variant 
present in the patient before treatment; and false reinfections, due to variants that are present but 
too infrequent to be detected in the pre-treatment PCR, but are then detectable post-treatment. This 
article aims to explore factors affecting the probability of false recrudescences and proposes a 
Monte Carlo uncertainty analysis to adjust for both types of misclassification. Higher levels of 
transmission intensity, increased multiplicity of infection, and limited allelic variation resulted in 
more false recrudescences. The uncertainty analysis exploits characteristics of study data to 
minimize bias in the estimate of efficacy and can be applied to areas of different transmission 
intensity.
Introduction
The World Health Organization (WHO) recommends that first-line antimalarial treatment 
policies be changed when a drug’s cure rate falls below 90%, and that new treatments not be 
recommended unless they have a cure rate greater than 95%.[1] However, defining the 
antimalarial cure rate is difficult in falciparum malaria clinical trials because recurrent 
parasitemias can result from either recrudescence (drug failure) or reinfection during follow-
up.
One tool used to distinguish between reinfection and recrudescence is PCR-correction (or 
PCR-adjustment). PCR-correction most often uses nested PCR (nPCR) to categorize 
recurrences by comparing size polymorphisms in genetic markers [merozoite surface 
proteins 1 and 2 (msp1, msp2) and glutamate rich protein (glurp)] before and after treatment. 
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PCR-correction of cure rates has been in use for more than 20 years and there is an extensive 
literature on the substantial impact it can have on estimates of treatment efficacy, as 
previously reviewed.[2, 3] Variations in PCR-correction techniques exist, especially with 
regard to the interpretation of results. In response to this variability, the Medicines for 
Malaria Venture (MMV) collaborated with the WHO to generate guidelines for PCR-
correction including a definition of a recrudescent infection, namely a recurrence in which 
one or more allelic variants are shared in the pre-treatment (day 0) sample and the recurrent 
(day R) parasitemia.[4]
PCR-correction is fallible. Incorrect identification of a reinfection as a recrudescence occurs 
when the patient is infected with same variant before and after treatment; this is more likely 
to occur in an area with limited allelic diversity or high transmission intensity.[5, 6] This 
type of misclassification results in underestimation of the cure rate. Additionally, there are 
often multiple genetically distinct allelic variants present within a single host and nPCR is 
not capable of detecting minority variants representing <20% of the population.[7] Thus, 
PCR-correction could misclassify a recrudescence as a reinfection because an apparently 
“new” variant which appears in the day R sample was present, but not detected, in the day 0 
sample.[8] This may be particularly important if drug resistant variants are at levels below 
detection initially but become more prevalent in the patient as other variants are cleared by 
the treatment. This type of misclassification results in overestimation of the cure rate.
This present work has two aims. First, to demonstrate the effect of the distribution of allelic 
variants, transmission intensity and multiplicity of infection (MOI) on the probability of 
misclassification of recurrent infections. Second, to develop a practical approach for 
adjusting PCR-corrected results for misclassification of both reinfections and 
recrudescences. A worked example using data from areas of both high and low transmission 
intensity is provided.
Methods
Characteristics affecting the probability of false positives
We used simulations of the infection, cure, and re-infection process to demonstrate the effect 
of allelic diversity, transmission intensity and MOI on the probability of a false positive. In 
this context, a false positive refers to a reinfection that is misclassified as a recrudescence 
because allelic variants in the day 0 and day R samples match by chance. We used MATLAB 
R2008a (Natick, MA) software to simulate infections (and re-infections) of individual 
patients after specifying the population-wide distribution of allelic variants. For each of 
100000 simulated patients, we assigned a specified number of day 0 variants drawn 
randomly from the distribution. We set treatment success at 100% and assigned a specified 
number of day R variants the same way. We tested all patients for matching day 0 and day R 
variants, and calculated the probability of a false positive as the number of patients with a 
match divided by 100000, the number of simulated patients.
We first assessed the effect of allelic diversity in the parasite population on the probability of 
a false positive. As in routine PCR-correction, allelic variants were distinguished by the 
number of base pairs (bp); due to the insensitivity of nPCR to small variations in the number 
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of bp, variants that were different by no more than 20bp were considered to be the same to 
replicate the degree of precision routinely allowed. We assumed that the sizes of the variants 
followed a normal distribution. We generated ten distributions, each with a mean equal to 
350bp (a relevant value based on the size of bands amplified during genotyping of msp1). 
Each distribution had a different variance; we included variances within the range of realistic 
values as well as extremes to demonstrate the effect of allelic diversity on false positives (the 
variances ranged from 1575 to 6475). The resulting distributions are shown in Figure 1. For 
each distribution, we simulated the infection and reinfection of 100000 patients by assigning 
each a single day 0 variant and a single day R variant drawn randomly from the distribution.
We assessed the effect of transmission intensity on the probability of a false positive by 
assigning each patient one day 0 variant and one, two, three or four day R variants, each 
reflecting an infectious bite (for simplicity, we assumed each infectious bite transmitted a 
single variant). We simulated the effect of MOI similarly, assigning each patient one through 
four day 0 variants and the same number of day R variants.
Monte Carlo uncertainty analysis
To accurately measure treatment success, estimates of the cure rate need to be adjusted for 
two types of misclassification: false positives (reinfections incorrectly being classified as 
recrudescent) and false negatives (true recrudescent infections misclassified as reinfections 
because a minority variant in the day 0 sample was not detected by nPCR). To adjust for this 
misclassification, we developed an uncertainty analysis that requires two sources of external, 
or prior, information: the distributions of false positives and false negatives. These 
distributions can be estimated using data from antimalarial efficacy studies.
We developed a method for estimating the distribution of false positives that reflects our 
understanding of the factors that influence the probability of a chance match and exploits 
characteristics of the study data themselves, allowing the probability of a false positive to 
appropriately be tailored to the study setting. False positive probabilities were calculated 
using the same simulation procedure described above, except that the number of allelic 
variants observed in each patient at day 0 and day R, and the population-wide distribution of 
allelic variants were set to match study data. We used MATLAB R2008a (Natick, MA) to 
simulate the infection and reinfection of N patients, where N was the number of patients 
who participated in the study. Each patient was assigned X day 0 and Y day R infections 
from the observed day 0 and day R distributions of allelic variants (the X for each patient 
was randomly selected from the observed distribution of the number of day 0 infections, the 
Y randomly selected from the distribution of the number of day R infections) and tested for 
matches. The false positive probability for this simulated study was then calculated as the 
number of chance matches divided by N. We repeated this process 10000 times (generating 
10000 false positive probabilities) and fit a normal distribution to their values; this provided 
the mean and variance for the distribution of the proportion of recrudescent infections that 
were false positives.
To estimate the distribution of false negatives, we made use of the observation that nPCR has 
limited sensitivity to variants comprising less than 20% of a patient’s parasite population.
[10,11] Misclassification of a recrudescence as a reinfection, a false negative, requires that 
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each day R variant be undetected in the day 0 variants, as a single shared variant will result 
in the classification of the recurrence as a recrudescence according to the MMV/WHO 
guidelines.[4] To our knowledge, the only published information on the role of false 
negatives comes from Juliano et al. who used heteroduplex tracking assays (HTAs), a 
molecular method more sensitive to minority variants and genetic variation than nPCR, and 
found that five of six new infections (83%) identified by PCR-correction were truly 
recrudescent infections.[8] However, their study population was at negligible risk of 
reinfection, likely making their results an overestimate in the context of an average 
antimalarial trial. Therefore, to estimate the proportion of reinfections that were false 
negatives we used the median number of variants observed in the day R samples, assumed 
each variant carried with it a 20% chance of being missed in the day 0 sample, and 
calculated the probability that all were missed at day 0 resulting in a false negative using this 
formula: proportion of false negatives equals (0.2)v, where v is the median number of 
variants. The 20% chance was based on existing literature and expert opinion. Figure 2 
shows our estimate of the effect of the number of variants in the day R sample on the 
probability that a recrudescence was misclassified as a reinfection (a false negative). We also 
conducted a sensitivity analysis varying the probability of a band being missed in the day 0 
sample from 0 to 80%.
We conducted a Monte Carlo uncertainty analysis to adjust the observed number of 
recrudescent infections as determined by PCR-correction after genotyping msp2 by the 
estimated distributions of false positives and false negatives. Using an approach similar to 
that described by Jurek et al.,[12] we calculate the adjusted cure rate using this formula:
(1)
Where Nt is the total number of patients, Nrecru is the number of recrudescent infections 
identified by PCR-correction, FP is the proportion of recrudescent infections that were false 
positives, Nnew is the number of reinfections identified by PCR-correction, and FN is the 
proportion of reinfections that were false negatives.
We used Oracle Crystal Ball, Fusion Edition (Redwood Shores, CA) software to run 100000 
trials in which the number of recrudescent infections as determined by PCR-correction after 
genotyping msp2 in each study area was adjusted and the cure rate calculated using formula 
1 (above). As the last step in each trial, we included a bootstrap step to allow for sampling 
error by generating a random value from a binomial distribution.[13] The binomial 
distribution is parameterized by n, the number of trials, and p, the probability of success. In 
this case, the number of trials equaled the number of patients in the study and the probability 
of success was the uncertainty-adjusted probability of treatment failure. We drew a single 
random value from the distribution and treated it as the number of recrudescences which 
allowed us to calculate the final cure rate, adjusted for both uncertainty and sampling error. 
We also ran 100000 trials without the bootstrap step to explore the effect of uncertainty in 
the absence of sampling error, and finally, also calculated traditional 95% confidence 
intervals around the PCR-corrected cure rate with no adjustment for outcome 
misclassification to demonstrate the effect of sampling error in the absence of uncertainty 
about the outcome.
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To provide an example of our proposed uncertainty analysis, we used genotyping data from 
two randomized antimalarial efficacy trials conducted in areas of differing transmission 
intensity. The data from the high transmission area came from a study in Tororo, Uganda 
(N=401); the researchers were comparing the efficacy of an amodiaquine plus artesunate 
regimen compared to an atemether-lumefantrine regimen.[14] The data from the low 
transmission area were generated by a study conducted in Bobo-Dioulasso, Burkina Faso 
(N=827); the researchers were comparing the efficacy of amodiaquine, sulfadoxine-
pyrimethamine and amodiaquine plus sulfadoxine-pyrimethamine.[15] In both studies, the 
different therapies did demonstrate different levels of efficacy[14, 15]; however, because we 
are not interested in a particular treatment’s efficacy, and instead are simply providing an 
example of the uncertainty analysis, we did not stratify by treatment arm. The data for each 
patient included the number and identity of allelic variants. Greenhouse et al. used two sets 
of primers for amplification to capture two allelic families of msp2, IC3D7 and FC27.[5] 
Alleles were considered different if they were from different allelic families or if they were 
not the same length.
Results
Characteristics affecting the probability of false positives
The simulations compared the effect of transmission intensity and MOI on the probability of 
a false positive across ten normal distributions comprising alleles with the same mean size 
(350bp) but different variances (Figure 1); increased variance signified higher levels of 
genetic diversity in the population under study. We drew 100000 samples of allelic variants 
from each distribution, assumed 100% treatment success, and drew a second variant to allow 
us to calculate the probability of a false positive. We calculated these probabilities at 
different levels of transmission intensity and different MOI.
At any level of allelic variance, the greater the number of post-treatment bites, or the more 
variants a patient had at day 0 and day R, the more likely a false positive. Conversely, higher 
levels of allelic diversity had lower probabilities of false positives regardless of transmission 
intensity or MOI (Figure 3).
Example of Monte Carlo uncertainty analysis
We used two data sets to provide examples of our Monte Carlo uncertainty analysis, which 
adjusted the number of recrudescent infections identified by PCR-correction by false 
positives (the proportion of nPCR identified recrudescent infections misclassified due to a 
variant in the day 0 and day R sample matching by chance) and false negatives (the 
proportion of nPCR reinfections misclassified due to nPCR insensitivity).
Patients from Tororo, the high transmission area, had one to eight day 0 variants (median of 
four) and one to eight day R variants (median of three). There were 40 variants in the day 0 
sample when divided into 20 base pair bins with variants ranging in size from 181 to 611bp. 
There were 38 variants in the day R sample with sizes ranging from 212 to 663bp.
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Patients from Bobo-Dioulasso, the low transmission area, had one to eight day 0 variants 
(median of two) and one to six day R variants (median of two). There were 39 variants in the 
day 0 sample with sizes ranging from 195 to 637bp. There were 25 variants in the day R 
sample with sizes ranging from 232 to 504bp.
False positives—There was slightly less allelic diversity in Bobo-Dioulasso, however 
individuals with single pre-treatment and post-treatment variants had very similar 
probabilities of a false positive (in Tororo the probability was 0.050 vs. 0.045 in Bobo-
Dioulasso). In patients with the sites’ median numbers of pre-treatment and post-treatment 
variants (four and three respectively in Tororo; two and two in Bobo-Dioulasso), the 
probability of a false positive was considerably higher in Tororo (0.327) when compared to 
Bobo-Dioulasso (0.163).
We used the probability of a day 0 and day R variant matching by chance to inform our 
distribution of false positives. We did this by running 10000 simulations, each with the 
number of participants in the study. Each participant was assigned X day 0 and Y day R 
variants from the observed day 0 and day R distributions of allelic variants (the X for each 
patient was randomly selected from the observed distribution of the number of day 0 
variants, the Y randomly selected from the distribution of the number of day R variants) and 
tested for matches. We created a distribution of these 10000 probabilities and determined its 
mean and standard error. The mean proportion of recrudescent infections that were false 
positives was 0.423 in Tororo (standard error = 0.0007) and 0.193 in Bobo-Dioulasso 
(standard error = 0.0004).
False negatives—False negatives occur when a minority variant is undetected by the 
nPCR and results in misclassification of a recrudescent infection as a reinfection. The 
proportion of variants likely to be false negatives was equal to (0.2)v, where 0.2 is the 
probability that a variant was missed in day 0 and v is the median number of variants in the 
site’s day R samples (Figure 2). The proportion of reinfections that were false negatives was 
0.008 in Tororo and 0.04 in Bobo-Dioulasso.
Adjusted number of recrudescent infections—There were 232 recurrent 
parasitemias among the 401 study participants from Tororo. After genotyping msp2, 145 
were classified as recrudescent and 87 as reinfection, corresponding to a cure rate of 63.8%. 
After conducting our uncertainty analysis, we determined that the 95% simulation interval of 
likely cure rates ranged from 74.6 to 83.3% (Table 1).
Among the 827 study participants from Bobo-Dioulasso, there were 75 recurrent 
parasitemias. After genotyping msp2, 50 were classified as recrudescent and 25 as 
reinfection, corresponding to a cure rate of 94.0%. After conducting our uncertainty 
analysis, we determined that the 95% simulation interval of likely cure rates ranged from 
93.5 to 96.5% (Table 1).
We evaluated the effect of uncertainty due to outcome misclassification and sampling error 
independently. The adjustment for uncertainty regarding outcome misclassification was 
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responsible for the upward shift of the cure rate (indicating greater efficacy) and sampling 
error increased the width of the simulation interval (Table 1).
Discussion
Our simulations demonstrated the effect of allelic diversity, transmission intensity and MOI 
on the probability of a chance match between a day 0 and day R variant. False positives were 
more common in areas with less diverse parasite populations and high transmission levels 
which would lead to underestimation of cure rates in those areas. The most dramatic 
increase in the probability of a false positive was associated with increased MOI (Figure 
3B).
The results of the proposed uncertainty analysis indicated false positives (reinfections 
misclassified as recrudescences) were responsible for the majority of misclassification in 
both examples. Selecting variants at random from the observed distributions in Tororo 
resulted in false positives in more than one-third of the recrudescent infections, while in 
Bobo-Dioulasso the probability that a recrudescence was a false positive was less than 20%. 
The discrepancy is primarily the result of the lower median day 0 and day R MOI in Bobo-
Dioulasso, as both areas had similar levels of allelic diversity. In Tororo, false positives 
resulted in an uncertainty interval of the cure rate that indicated greater efficacy than the 
original point estimate calculated after genotyping msp2.
False negatives (recrudescences misclassified as reinfections) resulted in only a small 
amount of misclassification for two reasons. First, multiple variants in the day R sample 
(observed in both study sites) decreased the probability of this type of misclassification 
exponentially (Figure 2). Our sensitivity analysis indicated that even with a 30% chance that 
a day 0 variant was not detected, the impact of the observed number of variants in the day R 
samples resulted in a negligible effect of false negatives (data not shown). As the chance a 
day 0 variant was not detected increased past 40%, the impact began to increase more 
rapidly, however values greater or equal to 30% are highly unlikely. Second, using PCR-
correction there were very few recurrences identified as reinfections; regardless of the 
probability that a reinfection was truly a recrudescence, the contribution of this type of 
misclassification to overall uncertainty would be low. However, in areas of low transmission, 
such as Southeast Asia, where few variants are present a day 0, false negatives may be an 
important source of misclassification.[8]
The uncertainty analysis was based on PCR-correction of a single marker. Though the use of 
multiple markers to perform PCR-correction (a common practice) may reduce the 
probability of false positives, it increases the probability of false negatives because the 
MMV/WHO guidelines state that a single marker classified as a reinfection results in the 
recurrence being classified as such, regardless of the classification of other markers 
genotyped. As additional information is generated regarding the probability of false 
negatives and how it changes with the use of multiple markers, it will be possible to refine 
this uncertainty analysis to accommodate multiple markers.
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The impact of misclassification with regard to WHO efficacy thresholds varied between the 
two sites. Although ultimately the range of likely cure rates in Tororo did not cross a WHO 
cut-point, it did demonstrate that misclassification plays an important role. In Bobo-
Dioulasso, the area of low transmission, a WHO cut-point was included in the interval of 
likely cure rates (i.e. 93.5 to 96.5%). The relatively few patients who had recurrent 
parasitemia in Bobo-Dioulasso resulted in a narrow interval of cure rates with values similar 
to the PCR-corrected point estimate, however a drug whose cure rate calculated the 
traditional way would have been just below the level of efficacy required for new drugs and 
may in turn have been rejected, when it should be eligible for consideration. 
Misclassification should always be considered when policy decisions are made based on 
estimates of efficacy.
Our approach to generating the distribution of false positives is probably not practical for 
use in all antimalarial efficacy studies. However, we are optimistic that it is possible to 
generate three reasonable “stock” distributions of false positives, one for high, medium, and 
low transmission areas. The uncertainty analysis itself is quite straightforward and can easily 
be carried out in Crystal Ball, a relatively inexpensive addition to Microsoft Excel, and 
perhaps eventually in a free web-based tool. It is our hope that future molecular research will 
allow us to provide researchers with distributions of false positives and false negatives, 
making this uncertainty analysis available for wide use.
Misclassification of recurrent parasitemias resulting from PCR-correction has been 
previously described. Adjustments of PCR-corrected trial results have been made using the 
distribution of allelic variants to calculate the probability of false positives leading to 
incorrect classification of the recurrence as a recrudescence when it is a reinfection.[5, 6, 16, 
17] HTAs, which use radiolabeled probes to bind to host amplicons, are more sensitive to 
minority variants and genetic variation than nPCR [6, 11, 18, 19] and have been used to 
demonstrate that nPCR insensitivity can result in recrudescent infections being misclassified 
as reinfections.[8] To our knowledge, simultaneous adjustment for both types of 
misclassification has not been undertaken previously.
Traditional confidence intervals summarize only the effect of random error and do not 
capture or reveal any uncertainty resulting from bias, including misclassification or 
measurement error, in the study. Adjusting results for misclassification was illustrated in 
previous work [12] and is grounded in methods proposed to estimate intervals that are an 
extension of traditional confidence intervals through use of simulations.[20] Some 
researchers are uncomfortable with the explicit assumptions about misclassification that are 
required for uncertainty analyses. However, this approach is far preferable to assuming 
misclassification is entirely absent, an implicit assumption in the traditional estimation of a 
PCR-corrected cure rate.
A point estimate of the cure rate, the traditional outcome measure in antimalarial efficacy 
studies, is insufficient given the limitations of PCR-correction. This insufficiency is even 
more important given the policy implications of efficacy estimates. A 95% simulation 
interval for the cure rate, instead of an estimate likely to be biased by outcome 
misclassification, may encourage more careful assessment of a treatment’s utility before 
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policy decisions are made. This work provides a template for adjusting for outcome 
misclassification in antimalarial efficacy studies that addresses both types of 
misclassification and can be applied to any study data that include information on the 
variants present in the patient population.
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Figure 1. The ten normal distributions of base pairs used for simulations
These distributions all have the same mean (350 bp); the variance increases from top to 
bottom. Each plot represents 100000 randomly assigned number of base pairs selected from 
the distribution. x-axis: number of base pairs; y-axis: frequency
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Figure 2. Multiplicity of infection and its effect on the probability of a false negative
A false negative, or a recrudescent infection misclassified as a reinfection, occurs as a result 
of nPCR insensitivity to minority variants (those comprising less than 20% of a patient’s 
infection).
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Figure 3. A) The effect of transmission intensity on the probability of a false positive, B) The 
effect of multiplicity of infection on the probability of a false positive
x-axis: measure of allelic variation in parasite population (1 = least variance); y-axis: 
probability of a false positive (a false positive occurs when a day 0 and day R variant match 
by chance); var = variant
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Table 1






Number of recurrent infections 232 75
Number of recrudescent infections identified by
PCR-correction based on genotyping of msp2
145 50
Cure rate (95% CIa) calculated by PCR-correction





95% SIb of likely cure rates adjusted for only for
uncertainty (%)c
77.4 – 80.5 94.9 – 95.1
95% SI of likely cure rates generated by Monte
Carlo uncertainty analysis (%)
74.6 – 83.3 93.5 – 96.5
a
. CI = confidence interval;
b
. SI = simulation interval;
c
. This interval does not take sampling error into account.
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